Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (419)	1/3/2000 3:44:00 PM
From: Marc Kahn	Read Replies (3) \| Respond to of 534

Hi Art, Happy new year to you! Clinical tests using Vical's Allovectin-7 are not using the Biojector as a delivery system. The drug is designed to be injected directly into tumors, where the DNA goes to work. Until recently, there was no way to deliver a Biojection internally. Bioject's collaboration with Angiosense is bound to change that. They are working on delivering an injection directly to the heart. Bioject is in clinical trials with 2 other Vical products which work in muscle tissue. They are Vaxid, a naked DNA vaccine to prevent relapse of B-cell lymphoma, which is mentioned in the article you posted a link to. Also, the malaria vaccine being tested by the US Navy is a Vical product. Hope this helps. Regards, Marc Kahn